1. Search Result
Search Result
Isoforms Recommended: Bim
Results for "

BIM

" in MedChemExpress (MCE) Product Catalog:

76

Inhibitors & Agonists

3

Biochemical Assay Reagents

29

Peptides

1

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50907
    ABT-737
    Maximum Cited Publications
    69 Publications Verification

    Bcl-2 Family Apoptosis Autophagy Mitophagy Inflammation/Immunology Cancer
    ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
    ABT-737
  • HY-19870
    Setmelanotide
    Maximum Cited Publications
    8 Publications Verification

    RM-493; BIM-22493; IRC-022493

    Melanocortin Receptor Metabolic Disease Endocrinology
    Setmelanotide (RM-493) is a selective melanocortin 4 receptor (MC4R) agonist with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively .
    Setmelanotide
  • HY-108742
    Abaloparatide
    3 Publications Verification

    BA 058; BIM 44058

    PTHR Arrestin Metabolic Disease Cancer
    Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
    Abaloparatide
  • HY-50868
    Bafetinib
    10+ Cited Publications

    INNO-406; NS-187

    Bcr-Abl Src Apoptosis Cancer
    Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
    Bafetinib
  • HY-15191
    Sabutoclax
    1 Publications Verification

    BI-97C1

    Bcl-2 Family Cancer
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression .
    Sabutoclax
  • HY-13313
    XL888
    5 Publications Verification

    HSP Apoptosis Cancer
    XL888 is a potent and orally active HSP90 inhibitor with an IC50 value of 24 nM. XL888 shows anti-proliferation activity and induces Apoptosis. XL888 shows anti-tumor activity .
    XL888
  • HY-114989
    Fluorizoline
    3 Publications Verification

    Apoptosis Cancer
    Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner .
    Fluorizoline
  • HY-19884B
    Relamorelin TFA
    1 Publications Verification

    RM-131 TFA; BIM-28131 TFA

    GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-118948
    MSN-50
    1 Publications Verification

    Bcl-2 Family Neurological Disease
    MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .
    MSN-50
  • HY-171830

    YX39-105

    PROTACs Tyrosinase Apoptosis Cancer
    MS105 (YX39-105) is an orally active and selective protein tyrosine kinase 6 (PTK6) (BRK) PROTAC degrader. MS105 recruits VHL E3 ligase via a VHL ligand moiety, promotes PTK6 ubiquitination and proteasomal degradation, inhibits the proliferation and migration of breast cancer cells, and induces apoptosis. MS105 shows potential for use in breast cancer research .
    MS105
  • HY-P1959

    BIM 23014

    Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .
    Lanreotide
  • HY-P1959A

    BIM 23014 acetate

    Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .
    Lanreotide acetate
  • HY-10499
    PH-064
    2 Publications Verification

    BIM-46187

    Serotonin Transporter Akt Neurological Disease Inflammation/Immunology Cancer
    PH-064 (BIM-46187) is an orally active inhibitor of the heterotrimeric G-protein complex. PH-064 inhibits SERT activity and attenuates shear stress-induced Akt phosphorylation. PH-064 has potent anti-hyperalgesia activity. PH-064 inhibits G protein-coupled receptor-dependent tumorigenesis. PH-064 can be used in the study of pain (e.g., inflammatory pain, neuropathic pain), GPCR-dependent tumors, and inflammatory lung injury .
    PH-064
  • HY-108136A
    Bisindolylmaleimide X hydrochloride
    2 Publications Verification

    BIM-X hydrochloride; Ro31-8425 hydrochloride

    PKC CDK Cardiovascular Disease Inflammation/Immunology Cancer
    Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .
    Bisindolylmaleimide X hydrochloride
  • HY-P1527
    Bim BH3
    1 Publications Verification

    Bcl-2 Family Others
    Bim BH3 is a biological active peptide. (This Bim peptide belongs to the pro-apoptotic Bcl-2 family of proteins.)
    Bim BH3
  • HY-P1889

    Bcl-2 Family Inflammation/Immunology
    Bim BH3, Peptide IV is a 26-residue peptide from BH3-only protein Bim, which belongs to the pro-apoptotic group of the Bcl-2 family of proteins .
    Bim BH3, Peptide IV
  • HY-P1203

    Somatostatin Receptor Neurological Disease
    BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively .
    BIM-23056
  • HY-W008325

    Amino Acid Derivatives Others
    Boc-L-Dap-OH is a Boc-protected derivative of L-2,3-diaminopropionic acid. Boc-L-Dap-OH is an important chiral amino acid derivative. Boc-L-Dap-OH can be generated via the Hofmann rearrangement of Boc-L-asparagine. Boc-L-Dap-OH serves as a starting material for the preparation of BIM analogs .
    Boc-L-Dap-OH
  • HY-P0165

    ITM077; R1583; BIM51077

    GCGR Metabolic Disease
    Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
    Taspoglutide
  • HY-19870C
    Setmelanotide monoacetate
    Maximum Cited Publications
    8 Publications Verification

    RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

    Melanocortin Receptor Calmodulin AMPK Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a Ki value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .
    Setmelanotide monoacetate
  • HY-115930

    Bcl-2 Family Cardiovascular Disease
    Bim-IN-1 is a potent Bim expression inhibitor. Bim-IN-1 reduces Bim expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity .
    Bim-IN-1
  • HY-101778

    EU-5346

    Bcl-2 Family Cancer
    ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction.
    ML311
  • HY-108742A
    Abaloparatide TFA
    3 Publications Verification

    BA 058 TFA; BIM 44058 TFA

    Arrestin PTHR Metabolic Disease Endocrinology Cancer
    Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
    Abaloparatide TFA
  • HY-W016510

    Biochemical Assay Reagents Drug Intermediate Others
    Benzenesulfonate sodium is the sodium salt of Benzenesulfonic acid. Benzenesulfonate sodium facilitates the identification of -SO3H and -SO3 - vibrational bands in compounds in Raman spectroscopy. Benzenesulfonate sodium was used in the synthesis of 1-Butyl-3-propanenitrile imidazolium benzenesulfonate [C2CN Bim]BS .
    Benzenesulfonate sodium
  • HY-P0039

    Bombesin Receptor Cancer
    BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC50 = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC50 values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth .
    BIM-26226
  • HY-P3124A

    Somatostatin Receptor Cancer
    BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    BIM-23190 hydrochloride
  • HY-15872

    Farnesyl Transferase Ras ERK mTOR Caspase Apoptosis Akt PI3K Bacterial Cardiovascular Disease Neurological Disease Cancer
    FTI-277 is a farnesyltransferase (FTase) inhibitor. FTI-277 inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
    FTI-277
  • HY-112400

    BIM V

    Ribosomal S6 Kinase (RSK) Cancer
    Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC50 value over 100 µM . Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70 s6k/p85 s6k (S6K) in vivo with an IC50 of 8 µM .
    Bisindolylmaleimide V
  • HY-19345

    NSC13316

    p38 MAPK Apoptosis Caspase Bcl-2 Family Cancer
    Vacquinol-1 (NSC13316) is a MKK4-specific activator that activates the MAPK pathway. Vacquinol-1 inhibits the growth, migration and colony formation, and induces apoptosis of cancer cells. Vacquinol-1 is applicable to research related to cancers such as hepatocellular carcinoma .
    Vacquinol-1
  • HY-110038

    Farnesyl Transferase Ras ERK mTOR Apoptosis Caspase Akt PI3K Bacterial Cardiovascular Disease Neurological Disease Cancer
    FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
    FTI-277 TFA
  • HY-103277

    Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    BIM 23042
  • HY-103277A
    BIM 23042 TFA
    1 Publications Verification

    Bombesin Receptor Neurological Disease Metabolic Disease
    BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca 2+ release .
    BIM 23042 TFA
  • HY-162008

    HSP Bcl-2 Family Cancer
    S1g-10 is a Hsp70/Bim inhibitor, and shows antitumor activity in chronic myeloid leukemia cells .
    S1g-10
  • HY-163854

    HSP Bcl-2 Family Apoptosis Cancer
    HSP70-IN-6 (Compound JL-15) is an inhibitor of Hsp70-Bim protein-protein interaction (PPI) (IC50: 70 nM). HSP70-IN-6 induces apoptosis in chronic myeloid leukemia (CML) cells, with EC50s of 0.43 μM(BV173), 0.88 μM (K562), 0.19 μM (K562-R3) .
    HSP70-IN-6
  • HY-121337

    R-40244

    Environmental Pollutants Apoptosis Bcl-2 Family Others
    Flurochloridone (R-40244) is a selective preemergence and persistent herbicide. Flurochloridone induces endoplasmic reticulum (ER) stress and activated unfolded protein response (UPR) signaling pathways. Flurochloridone impairs cell viability and induces cytotoxicity and apoptosis mediated by ER stress via activating eIF2α-ATF4/ATF6-CHOP-Bim/Bax signaling pathways in TM4 cells .
    Flurochloridone
  • HY-P1207

    Somatostatin Receptor Neurological Disease
    BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .
    BIM 23052
  • HY-121683

    16:1 Aldehyde; trans-2-Hexadecenal

    Mixed Lineage Kinase Apoptosis JNK Microtubule/Tubulin Cancer
    (E)-2-Hexadecenal (trans-2-Hexadecenal) is an MLK3 activator that induces cytoskeletal remodeling, leading to cell rounding, detachment, and ultimately apoptosis in human and mouse cells. (E)-2-Hexadecenal activates the MLK3 signaling pathway, phosphorylating MKK4/7 and JNK, subsequently activating downstream targets of JNK, such as c-Jun phosphorylation, cytochrome c release, Bax activation, Bid cleavage, and Bim translocation to mitochondria. (E)-2-Hexadecenal has potential applications in research related to sphingolipid signaling pathways .
    (E)-2-Hexadecenal
  • HY-P3124

    Somatostatin Receptor Cancer
    BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    BIM-23190
  • HY-P3294

    BIM-23A760; TBR-760

    Dopamine Receptor Somatostatin Receptor Neurological Disease Cancer
    Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .
    Onzigolide
  • HY-19884

    RM-131; BIM-28131

    GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-117893

    Farnesyl Transferase Ras Cancer
    BIM-46068 is a potent, selectively human brain Farnesyltransferase (FTase) inhibitor (IC50 = 91.4 nM). BIM-46068 can specifically inhibit Ras processing in MiaPaCa-2 cancer cells. BIM-46068 can be used for the study of pancreatic cancer .
    BIM-46068
  • HY-P3958

    Somatostatin Receptor Dopamine Receptor Neurological Disease
    BIM-23027 is a selective agonist of sst2 receptor (EC50=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism .
    BIM-23027
  • HY-119971

    Nuclear Hormone Receptor 4A/NR4A Metabolic Disease Cancer
    BIM5078 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BIM5078 represses insulin promoter activity through HNF4α antagonism. BIM5078 can be used for the research of cancer and diabetes .
    BIM5078
  • HY-19884A

    RM-131 acetate; BIM-28131 acetate

    GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-19870A

    RM-493 TFA; BIM-22493 TFA; IRC-022493 TFA

    Melanocortin Receptor Metabolic Disease Endocrinology
    Setmelanotide TFA (RM-493 TFA) is a selective melanocortin 4 receptor (MC4R) agonist with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively .
    Setmelanotide TFA
  • HY-115806

    Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism Neurological Disease
    TC9-305 is a potent and selective apoptosis inhibitor. TC9-305 has strong inhibitory activity against both Bim and tBid-induced apoptosis with EC50 values of 0.42 and 0.23 μM. TC9-305 can maintain the mitochondrial membrane potential, reduce ROS production, prevent the release of cytochrome c and block the upstream pathways of mitochondrial-mediated apoptosis. TC9-305 can be used for the research of neurological disease, such as storke .
    TC9-305
  • HY-P2028

    GnRH Receptor Cancer
    BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .
    BIM 21009
  • HY-175273

    PROTACs FLT3 HSP ERK STAT Akt Apoptosis Cancer
    MA191 is a FLT3 PROTAC degrader. MA191 abrogates FLT3 inhibitor resistance from rebound activation of mitogen-activated kinases. MA191 mediates rapid FLT3-ITD degradation through a mechanism requiring VHL, neddylation, and BIM. MA191 reduces FLT3-ITD levels before inducing apoptosis. MA191 halts AML cell proliferation in Danio rerio. MA191 can be used for the study of acute myeloid leukemia (AML) (Pink: FLT3 ligand: (HY-175311), Blue: E3 ligase CRBN Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175312)) .
    MA191
  • HY-179012

    APC CDK Raf Akt HSP Cancer
    CDC20/HSP90-IN-1 (Compound 2b) is a Cdc20/Hsp90 inhibitor with a Kd of 16.2 μM for Cdc20 and a Kd of 0.241 μM for Hsp90α. CDC20/HSP90-IN-1 exerts potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. CDC20/HSP90-IN-1 overcomes Vemurafenib (HY-12057)-induced resistant melanoma .
    CDC20/HSP90-IN-1
  • HY-P1959B

    BIM 23014 diTFA

    Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .
    Lanreotide diTFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: